| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intracellular Signaling Peptides and Proteins | 24 | 2025 | 285 | 9.480 |
Why?
|
| Pancreatic Neoplasms | 28 | 2025 | 546 | 5.450 |
Why?
|
| Neoplastic Stem Cells | 19 | 2023 | 141 | 3.900 |
Why?
|
| Carcinoma, Pancreatic Ductal | 12 | 2025 | 144 | 3.890 |
Why?
|
| Stem Cells | 18 | 2017 | 122 | 3.050 |
Why?
|
| MicroRNAs | 13 | 2024 | 301 | 2.850 |
Why?
|
| Biomarkers, Tumor | 16 | 2025 | 409 | 2.680 |
Why?
|
| Intestinal Mucosa | 24 | 2018 | 197 | 2.590 |
Why?
|
| Epithelial Cells | 16 | 2020 | 256 | 2.220 |
Why?
|
| Epithelial-Mesenchymal Transition | 13 | 2021 | 115 | 2.190 |
Why?
|
| Adenocarcinoma | 14 | 2020 | 300 | 2.110 |
Why?
|
| Colonic Neoplasms | 15 | 2017 | 121 | 2.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 19 | 2021 | 465 | 2.070 |
Why?
|
| Mice | 65 | 2025 | 4732 | 2.040 |
Why?
|
| Liver Neoplasms | 7 | 2024 | 167 | 1.960 |
Why?
|
| Cell Proliferation | 29 | 2025 | 815 | 1.860 |
Why?
|
| Animals | 73 | 2025 | 10580 | 1.760 |
Why?
|
| Cell Line, Tumor | 35 | 2025 | 1338 | 1.740 |
Why?
|
| Colorectal Neoplasms | 9 | 2022 | 141 | 1.700 |
Why?
|
| RNA-Binding Proteins | 16 | 2014 | 87 | 1.570 |
Why?
|
| Intestines | 8 | 2016 | 118 | 1.420 |
Why?
|
| Carcinoma, Hepatocellular | 7 | 2024 | 133 | 1.340 |
Why?
|
| Alternative Splicing | 3 | 2020 | 48 | 1.280 |
Why?
|
| Humans | 83 | 2025 | 28581 | 1.270 |
Why?
|
| Apoptosis | 23 | 2018 | 777 | 1.240 |
Why?
|
| Signal Transduction | 15 | 2025 | 1454 | 1.200 |
Why?
|
| Cell Survival | 11 | 2017 | 416 | 1.130 |
Why?
|
| Liver Cirrhosis | 4 | 2024 | 74 | 1.130 |
Why?
|
| Inflammation | 4 | 2024 | 641 | 1.110 |
Why?
|
| Intestine, Small | 5 | 2015 | 66 | 1.090 |
Why?
|
| RNA, Messenger | 24 | 2015 | 667 | 1.080 |
Why?
|
| Colon | 10 | 2020 | 121 | 1.070 |
Why?
|
| Whole-Body Irradiation | 5 | 2016 | 40 | 1.060 |
Why?
|
| Immunotherapy | 4 | 2025 | 160 | 1.030 |
Why?
|
| Antineoplastic Agents | 7 | 2018 | 681 | 1.020 |
Why?
|
| Dinoprostone | 10 | 2016 | 42 | 0.990 |
Why?
|
| Mice, Nude | 16 | 2019 | 332 | 0.980 |
Why?
|
| Radiation Injuries, Experimental | 4 | 2015 | 31 | 0.980 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2018 | 77 | 0.980 |
Why?
|
| Radiation Injuries | 3 | 2016 | 52 | 0.970 |
Why?
|
| Nerve Tissue Proteins | 14 | 2012 | 154 | 0.960 |
Why?
|
| Gelsolin | 1 | 2025 | 7 | 0.950 |
Why?
|
| Kidney Neoplasms | 2 | 2018 | 101 | 0.950 |
Why?
|
| Barrett Esophagus | 3 | 2014 | 16 | 0.930 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2019 | 170 | 0.930 |
Why?
|
| Gene Deletion | 3 | 2015 | 120 | 0.880 |
Why?
|
| Tumor Microenvironment | 6 | 2025 | 186 | 0.880 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2025 | 274 | 0.870 |
Why?
|
| Benzodiazepinones | 2 | 2014 | 13 | 0.870 |
Why?
|
| Colitis | 5 | 2018 | 54 | 0.870 |
Why?
|
| beta Catenin | 4 | 2022 | 66 | 0.860 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2020 | 120 | 0.860 |
Why?
|
| Databases, Factual | 2 | 2024 | 265 | 0.830 |
Why?
|
| Liver Transplantation | 1 | 2024 | 56 | 0.820 |
Why?
|
| Peptides | 2 | 2025 | 293 | 0.820 |
Why?
|
| Cyclooxygenase 2 | 15 | 2016 | 68 | 0.800 |
Why?
|
| Cation Transport Proteins | 6 | 2025 | 60 | 0.800 |
Why?
|
| Esophageal Neoplasms | 2 | 2014 | 32 | 0.800 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2024 | 75 | 0.790 |
Why?
|
| Neoplasms | 4 | 2025 | 857 | 0.780 |
Why?
|
| Hepacivirus | 2 | 2013 | 48 | 0.760 |
Why?
|
| Hepatocytes | 2 | 2020 | 80 | 0.730 |
Why?
|
| Intestinal Neoplasms | 2 | 2014 | 15 | 0.720 |
Why?
|
| Receptor, Notch1 | 4 | 2017 | 27 | 0.680 |
Why?
|
| Prostaglandin D2 | 1 | 2020 | 6 | 0.670 |
Why?
|
| Gene Expression Regulation | 8 | 2017 | 633 | 0.670 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 10 | 2015 | 328 | 0.670 |
Why?
|
| Cell Movement | 7 | 2021 | 373 | 0.660 |
Why?
|
| Mice, Inbred C57BL | 17 | 2020 | 1601 | 0.650 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 45 | 0.640 |
Why?
|
| Gene Knockdown Techniques | 3 | 2019 | 134 | 0.630 |
Why?
|
| Carcinogenesis | 4 | 2024 | 81 | 0.590 |
Why?
|
| RNA Interference | 6 | 2015 | 137 | 0.580 |
Why?
|
| Dextran Sulfate | 3 | 2015 | 9 | 0.580 |
Why?
|
| DNA Damage | 3 | 2022 | 151 | 0.580 |
Why?
|
| Gene Expression Profiling | 5 | 2017 | 453 | 0.570 |
Why?
|
| Cell Differentiation | 4 | 2015 | 419 | 0.570 |
Why?
|
| Receptors, Notch | 4 | 2014 | 44 | 0.570 |
Why?
|
| Blotting, Western | 12 | 2016 | 515 | 0.560 |
Why?
|
| Survival Analysis | 6 | 2021 | 288 | 0.560 |
Why?
|
| Spheroids, Cellular | 8 | 2021 | 53 | 0.560 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 4 | 2021 | 26 | 0.550 |
Why?
|
| Radiation-Protective Agents | 2 | 2015 | 22 | 0.540 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2022 | 155 | 0.540 |
Why?
|
| Mitosis | 8 | 2013 | 115 | 0.530 |
Why?
|
| Cell Self Renewal | 1 | 2017 | 8 | 0.530 |
Why?
|
| Microtubules | 2 | 2016 | 90 | 0.520 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 15 | 0.520 |
Why?
|
| RNAi Therapeutics | 2 | 2015 | 13 | 0.510 |
Why?
|
| Proto-Oncogene Proteins c-myc | 4 | 2025 | 44 | 0.500 |
Why?
|
| Female | 23 | 2025 | 15471 | 0.500 |
Why?
|
| Male | 24 | 2025 | 13771 | 0.500 |
Why?
|
| Neovascularization, Pathologic | 4 | 2013 | 148 | 0.490 |
Why?
|
| Isoenzymes | 7 | 2014 | 86 | 0.490 |
Why?
|
| Cachexia | 3 | 2022 | 53 | 0.490 |
Why?
|
| Disease Progression | 7 | 2025 | 475 | 0.490 |
Why?
|
| Immunohistochemistry | 9 | 2018 | 465 | 0.490 |
Why?
|
| Pancreas | 2 | 2020 | 63 | 0.480 |
Why?
|
| Pectins | 1 | 2015 | 7 | 0.480 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2016 | 41 | 0.480 |
Why?
|
| Disease Models, Animal | 10 | 2018 | 1494 | 0.480 |
Why?
|
| Mucositis | 1 | 2015 | 7 | 0.470 |
Why?
|
| Receptors, Prostaglandin E | 2 | 2007 | 6 | 0.460 |
Why?
|
| Focal Adhesions | 1 | 2015 | 15 | 0.460 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 25 | 0.460 |
Why?
|
| RNA, Small Interfering | 7 | 2018 | 198 | 0.460 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2014 | 13 | 0.450 |
Why?
|
| Genetic Therapy | 1 | 2015 | 124 | 0.450 |
Why?
|
| Antigens, Surface | 3 | 2009 | 39 | 0.440 |
Why?
|
| Carcinoma | 2 | 2014 | 74 | 0.440 |
Why?
|
| Transcription Factors | 5 | 2021 | 523 | 0.440 |
Why?
|
| Flow Cytometry | 7 | 2016 | 291 | 0.440 |
Why?
|
| RNA, Neoplasm | 4 | 2008 | 24 | 0.440 |
Why?
|
| Mice, Transgenic | 5 | 2017 | 509 | 0.430 |
Why?
|
| Neoplasm Proteins | 3 | 2009 | 123 | 0.420 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2013 | 22 | 0.420 |
Why?
|
| Receptors, G-Protein-Coupled | 3 | 2014 | 78 | 0.420 |
Why?
|
| Histones | 4 | 2012 | 95 | 0.420 |
Why?
|
| 3' Untranslated Regions | 5 | 2009 | 34 | 0.410 |
Why?
|
| Virus Replication | 1 | 2013 | 66 | 0.410 |
Why?
|
| Mice, Knockout | 11 | 2020 | 861 | 0.410 |
Why?
|
| Gastrointestinal Tract | 3 | 2015 | 35 | 0.410 |
Why?
|
| Pyrimidines | 1 | 2014 | 128 | 0.400 |
Why?
|
| Wound Healing | 1 | 2014 | 126 | 0.400 |
Why?
|
| Exonucleases | 2 | 2011 | 5 | 0.400 |
Why?
|
| Tumor Burden | 4 | 2015 | 110 | 0.400 |
Why?
|
| Tumor Cells, Cultured | 7 | 2018 | 314 | 0.390 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 164 | 0.390 |
Why?
|
| Indoles | 1 | 2013 | 110 | 0.390 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 6 | 2004 | 24 | 0.390 |
Why?
|
| Up-Regulation | 4 | 2015 | 247 | 0.390 |
Why?
|
| Protein Isoforms | 3 | 2023 | 119 | 0.380 |
Why?
|
| Biomarkers | 7 | 2022 | 770 | 0.380 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2009 | 29 | 0.370 |
Why?
|
| Gene Expression | 4 | 2015 | 417 | 0.370 |
Why?
|
| Curcumin | 5 | 2015 | 69 | 0.360 |
Why?
|
| Esophagus | 1 | 2012 | 70 | 0.360 |
Why?
|
| Extracellular Vesicles | 2 | 2025 | 48 | 0.360 |
Why?
|
| Protein Binding | 6 | 2025 | 664 | 0.360 |
Why?
|
| RNA, Viral | 1 | 2011 | 68 | 0.350 |
Why?
|
| Membrane Proteins | 7 | 2006 | 485 | 0.340 |
Why?
|
| Nanoparticles | 2 | 2012 | 291 | 0.340 |
Why?
|
| HCT116 Cells | 11 | 2015 | 53 | 0.340 |
Why?
|
| Cisplatin | 2 | 2019 | 183 | 0.320 |
Why?
|
| Cyclooxygenase 1 | 3 | 2006 | 9 | 0.320 |
Why?
|
| Middle Aged | 5 | 2024 | 7310 | 0.310 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2009 | 2 | 0.310 |
Why?
|
| Tristetraprolin | 1 | 2009 | 4 | 0.310 |
Why?
|
| Protein Biosynthesis | 6 | 2011 | 111 | 0.290 |
Why?
|
| Prognosis | 4 | 2025 | 807 | 0.290 |
Why?
|
| Repressor Proteins | 5 | 2014 | 119 | 0.280 |
Why?
|
| Azoxymethane | 2 | 2013 | 20 | 0.280 |
Why?
|
| Phosphorylation | 8 | 2022 | 581 | 0.280 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2007 | 10 | 0.280 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2013 | 135 | 0.270 |
Why?
|
| Aged | 3 | 2024 | 5525 | 0.270 |
Why?
|
| Cell Cycle | 8 | 2016 | 162 | 0.260 |
Why?
|
| Transplantation, Heterologous | 4 | 2011 | 60 | 0.260 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2021 | 163 | 0.250 |
Why?
|
| Real-Time Polymerase Chain Reaction | 4 | 2015 | 133 | 0.250 |
Why?
|
| Lectins, C-Type | 3 | 2013 | 43 | 0.240 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 3 | 2022 | 42 | 0.240 |
Why?
|
| Pancreatitis | 2 | 2016 | 36 | 0.240 |
Why?
|
| Chronic Disease | 2 | 2024 | 273 | 0.230 |
Why?
|
| Down-Regulation | 4 | 2014 | 200 | 0.230 |
Why?
|
| HLA Antigens | 1 | 2025 | 61 | 0.230 |
Why?
|
| Antigens, Neoplasm | 1 | 2025 | 56 | 0.220 |
Why?
|
| Neoplasm Metastasis | 5 | 2021 | 164 | 0.220 |
Why?
|
| Immunoenzyme Techniques | 3 | 2015 | 66 | 0.220 |
Why?
|
| Stromal Cells | 2 | 2015 | 62 | 0.220 |
Why?
|
| Zinc | 2 | 2025 | 63 | 0.220 |
Why?
|
| Microglia | 1 | 2025 | 68 | 0.220 |
Why?
|
| Epitopes | 1 | 2025 | 185 | 0.210 |
Why?
|
| Antiviral Agents | 2 | 2016 | 114 | 0.210 |
Why?
|
| Glioblastoma | 1 | 2025 | 109 | 0.210 |
Why?
|
| Epigenesis, Genetic | 2 | 2023 | 148 | 0.210 |
Why?
|
| Liver Diseases | 1 | 2024 | 52 | 0.210 |
Why?
|
| Integrin alpha3 | 2 | 2021 | 18 | 0.200 |
Why?
|
| Heterografts | 2 | 2020 | 66 | 0.200 |
Why?
|
| Transfection | 6 | 2015 | 319 | 0.200 |
Why?
|
| Fibroblast Growth Factors | 1 | 2003 | 24 | 0.200 |
Why?
|
| Curcuma | 2 | 2015 | 8 | 0.200 |
Why?
|
| Case-Control Studies | 2 | 2015 | 732 | 0.190 |
Why?
|
| ras Proteins | 2 | 2014 | 43 | 0.190 |
Why?
|
| Phenotype | 2 | 2015 | 682 | 0.190 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2003 | 44 | 0.190 |
Why?
|
| Acetate-CoA Ligase | 1 | 2022 | 9 | 0.190 |
Why?
|
| Survival Rate | 3 | 2019 | 431 | 0.190 |
Why?
|
| Gastric Mucosa | 2 | 2015 | 35 | 0.190 |
Why?
|
| Prostaglandin Antagonists | 1 | 2001 | 1 | 0.190 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2022 | 39 | 0.180 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2001 | 25 | 0.180 |
Why?
|
| Sensitivity and Specificity | 5 | 2018 | 524 | 0.180 |
Why?
|
| Brain Neoplasms | 1 | 2025 | 311 | 0.180 |
Why?
|
| Mice, Inbred BALB C | 6 | 2011 | 278 | 0.180 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2001 | 45 | 0.180 |
Why?
|
| Transforming Growth Factor beta | 1 | 2022 | 79 | 0.180 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2001 | 78 | 0.170 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2020 | 135 | 0.170 |
Why?
|
| Exosomes | 1 | 2023 | 96 | 0.170 |
Why?
|
| Cells, Cultured | 3 | 2015 | 1009 | 0.170 |
Why?
|
| Cell Plasticity | 1 | 2021 | 10 | 0.170 |
Why?
|
| Adenosine | 1 | 2021 | 33 | 0.170 |
Why?
|
| Cellular Senescence | 2 | 2014 | 126 | 0.170 |
Why?
|
| RNA Stability | 5 | 2008 | 28 | 0.170 |
Why?
|
| Mucin-2 | 1 | 2020 | 6 | 0.170 |
Why?
|
| Mucus | 1 | 2020 | 13 | 0.170 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2014 | 140 | 0.170 |
Why?
|
| SOX9 Transcription Factor | 1 | 2020 | 12 | 0.170 |
Why?
|
| alpha-Fetoproteins | 1 | 2020 | 18 | 0.170 |
Why?
|
| Hep G2 Cells | 1 | 2020 | 31 | 0.170 |
Why?
|
| Time Factors | 3 | 2015 | 1600 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 340 | 0.160 |
Why?
|
| 14-3-3 Proteins | 2 | 2011 | 9 | 0.160 |
Why?
|
| Mutation | 2 | 2017 | 864 | 0.160 |
Why?
|
| Macrophage Activation | 1 | 2020 | 32 | 0.160 |
Why?
|
| Exoribonucleases | 2 | 2011 | 20 | 0.160 |
Why?
|
| Integrin beta1 | 1 | 2019 | 15 | 0.160 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 48 | 0.160 |
Why?
|
| Deoxycytidine | 1 | 2019 | 65 | 0.150 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1999 | 29 | 0.150 |
Why?
|
| Genes, APC | 2 | 2017 | 14 | 0.150 |
Why?
|
| Adult | 3 | 2024 | 7922 | 0.150 |
Why?
|
| Risk Factors | 1 | 2024 | 2111 | 0.150 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2011 | 179 | 0.140 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2018 | 40 | 0.140 |
Why?
|
| Claudin-1 | 1 | 2018 | 7 | 0.140 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2018 | 17 | 0.140 |
Why?
|
| Enterococcus faecalis | 2 | 2008 | 71 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 3 | 2015 | 344 | 0.140 |
Why?
|
| United States | 1 | 2024 | 2201 | 0.140 |
Why?
|
| Stilbenes | 2 | 2016 | 90 | 0.140 |
Why?
|
| Enteroendocrine Cells | 1 | 2017 | 1 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2011 | 194 | 0.140 |
Why?
|
| Antigens, Differentiation | 1 | 2017 | 21 | 0.140 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 478 | 0.140 |
Why?
|
| Jejunum | 1 | 2017 | 9 | 0.140 |
Why?
|
| RNA Processing, Post-Transcriptional | 3 | 2013 | 20 | 0.140 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2014 | 30 | 0.130 |
Why?
|
| CELF Proteins | 8 | 2011 | 12 | 0.130 |
Why?
|
| Enterocytes | 1 | 2016 | 15 | 0.130 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2008 | 19 | 0.130 |
Why?
|
| Transcription, Genetic | 3 | 2020 | 404 | 0.130 |
Why?
|
| Cell Membrane Permeability | 1 | 2016 | 44 | 0.130 |
Why?
|
| Cluster Analysis | 1 | 2017 | 126 | 0.130 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 32 | 0.130 |
Why?
|
| Integrases | 1 | 2016 | 39 | 0.130 |
Why?
|
| Neoplasm Transplantation | 3 | 2019 | 90 | 0.130 |
Why?
|
| DNA Methylation | 2 | 2015 | 152 | 0.130 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2016 | 12 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 257 | 0.120 |
Why?
|
| Mucins | 1 | 2016 | 25 | 0.120 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 32 | 0.120 |
Why?
|
| CA-125 Antigen | 1 | 2016 | 19 | 0.120 |
Why?
|
| Databases, Genetic | 1 | 2015 | 49 | 0.120 |
Why?
|
| Polysaccharides | 1 | 2016 | 63 | 0.120 |
Why?
|
| Bone Resorption | 1 | 2015 | 23 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 75 | 0.120 |
Why?
|
| Tissue Distribution | 2 | 2010 | 137 | 0.120 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 1026 | 0.120 |
Why?
|
| CA-19-9 Antigen | 1 | 2015 | 7 | 0.120 |
Why?
|
| DNA-Binding Proteins | 2 | 2022 | 490 | 0.120 |
Why?
|
| Thrombin | 1 | 2015 | 69 | 0.120 |
Why?
|
| Pyrroles | 1 | 2015 | 36 | 0.120 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 2 | 2007 | 4 | 0.120 |
Why?
|
| Esophagoscopy | 1 | 2014 | 16 | 0.110 |
Why?
|
| Cell Culture Techniques | 2 | 2013 | 117 | 0.110 |
Why?
|
| Random Allocation | 2 | 2018 | 151 | 0.110 |
Why?
|
| Plant Extracts | 1 | 2015 | 62 | 0.110 |
Why?
|
| Diffusion Chambers, Culture | 1 | 2014 | 6 | 0.110 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2014 | 5 | 0.110 |
Why?
|
| Longevity | 1 | 2015 | 134 | 0.110 |
Why?
|
| Pancreatitis-Associated Proteins | 4 | 2022 | 6 | 0.110 |
Why?
|
| Laminin | 1 | 2014 | 21 | 0.110 |
Why?
|
| Mice, SCID | 1 | 2014 | 60 | 0.110 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 50 | 0.110 |
Why?
|
| Paneth Cells | 1 | 2014 | 8 | 0.110 |
Why?
|
| Proteoglycans | 1 | 2014 | 38 | 0.110 |
Why?
|
| Lentivirus | 1 | 2014 | 16 | 0.110 |
Why?
|
| Drug Combinations | 1 | 2014 | 50 | 0.110 |
Why?
|
| Stem Cell Niche | 1 | 2014 | 12 | 0.110 |
Why?
|
| Molecular Docking Simulation | 1 | 2014 | 52 | 0.110 |
Why?
|
| Peptide Fragments | 1 | 2015 | 202 | 0.110 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2014 | 22 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2004 | 94 | 0.110 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 61 | 0.110 |
Why?
|
| Transcriptome | 1 | 2015 | 214 | 0.110 |
Why?
|
| Adenoma | 1 | 2014 | 61 | 0.110 |
Why?
|
| Interleukin-8 | 3 | 2008 | 45 | 0.110 |
Why?
|
| Myofibroblasts | 1 | 2014 | 23 | 0.110 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2014 | 41 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2009 | 68 | 0.100 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2013 | 15 | 0.100 |
Why?
|
| Surface Properties | 1 | 2014 | 134 | 0.100 |
Why?
|
| Interferon Type I | 2 | 2011 | 56 | 0.100 |
Why?
|
| Wnt Signaling Pathway | 1 | 2014 | 58 | 0.100 |
Why?
|
| Genetic Vectors | 1 | 2014 | 118 | 0.100 |
Why?
|
| Cell Lineage | 2 | 2014 | 51 | 0.100 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2013 | 31 | 0.100 |
Why?
|
| Gene Silencing | 1 | 2013 | 65 | 0.100 |
Why?
|
| Binding Sites | 1 | 2014 | 354 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 480 | 0.100 |
Why?
|
| Caspase 3 | 3 | 2008 | 58 | 0.100 |
Why?
|
| Homeodomain Proteins | 2 | 2011 | 79 | 0.100 |
Why?
|
| Collagen | 1 | 2014 | 156 | 0.100 |
Why?
|
| Bacterial Infections | 1 | 2013 | 56 | 0.100 |
Why?
|
| Dietary Supplements | 1 | 2015 | 265 | 0.100 |
Why?
|
| Liver | 2 | 2016 | 456 | 0.100 |
Why?
|
| Crohn Disease | 2 | 2003 | 31 | 0.100 |
Why?
|
| Colitis, Ulcerative | 2 | 2003 | 31 | 0.100 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2009 | 13 | 0.100 |
Why?
|
| Cell Cycle Proteins | 4 | 2022 | 187 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 2 | 2025 | 97 | 0.090 |
Why?
|
| ELAV Proteins | 2 | 2009 | 4 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2010 | 108 | 0.090 |
Why?
|
| Microarray Analysis | 1 | 2012 | 64 | 0.090 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2009 | 49 | 0.090 |
Why?
|
| Muscles | 2 | 2022 | 73 | 0.090 |
Why?
|
| Interferon Inducers | 1 | 2011 | 3 | 0.090 |
Why?
|
| Polyglycolic Acid | 1 | 2012 | 38 | 0.090 |
Why?
|
| Replicon | 1 | 2011 | 7 | 0.090 |
Why?
|
| Keratin-19 | 1 | 2011 | 5 | 0.090 |
Why?
|
| Aminoquinolines | 1 | 2011 | 11 | 0.090 |
Why?
|
| Breast Neoplasms | 2 | 2010 | 472 | 0.090 |
Why?
|
| Dipeptides | 1 | 2011 | 22 | 0.090 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2011 | 20 | 0.090 |
Why?
|
| ELAV-Like Protein 1 | 2 | 2009 | 30 | 0.090 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2011 | 34 | 0.090 |
Why?
|
| Lactic Acid | 1 | 2012 | 94 | 0.090 |
Why?
|
| Glycosylation | 3 | 2020 | 70 | 0.090 |
Why?
|
| Hepatitis C | 1 | 2011 | 41 | 0.090 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2011 | 4 | 0.090 |
Why?
|
| Twist-Related Protein 1 | 1 | 2011 | 5 | 0.090 |
Why?
|
| Stomach Neoplasms | 2 | 2008 | 25 | 0.090 |
Why?
|
| Neoplasms, Experimental | 2 | 2008 | 58 | 0.090 |
Why?
|
| Recombinant Proteins | 5 | 2008 | 415 | 0.090 |
Why?
|
| Vimentin | 1 | 2011 | 28 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2014 | 1272 | 0.090 |
Why?
|
| I-kappa B Proteins | 1 | 2010 | 11 | 0.090 |
Why?
|
| Caspase 7 | 2 | 2008 | 5 | 0.080 |
Why?
|
| Nestin | 1 | 2010 | 10 | 0.080 |
Why?
|
| Protein Transport | 2 | 2007 | 158 | 0.080 |
Why?
|
| Intermediate Filament Proteins | 1 | 2010 | 21 | 0.080 |
Why?
|
| Cell Separation | 1 | 2010 | 55 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2025 | 2402 | 0.080 |
Why?
|
| Arsenic | 1 | 2010 | 19 | 0.080 |
Why?
|
| HT29 Cells | 4 | 2015 | 20 | 0.080 |
Why?
|
| Bromodeoxyuridine | 1 | 2009 | 9 | 0.080 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2010 | 53 | 0.080 |
Why?
|
| Organoids | 2 | 2022 | 23 | 0.080 |
Why?
|
| Lithostathine | 2 | 2006 | 2 | 0.080 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2009 | 5 | 0.080 |
Why?
|
| Cell Division | 1 | 2009 | 154 | 0.080 |
Why?
|
| Gene Knockout Techniques | 1 | 2009 | 36 | 0.080 |
Why?
|
| Probability | 1 | 2009 | 78 | 0.080 |
Why?
|
| Aegle | 1 | 2008 | 2 | 0.070 |
Why?
|
| Naphthols | 1 | 2008 | 6 | 0.070 |
Why?
|
| Retrospective Studies | 1 | 2015 | 2612 | 0.070 |
Why?
|
| Aneuploidy | 1 | 2008 | 21 | 0.070 |
Why?
|
| Hemin | 1 | 2008 | 14 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 104 | 0.070 |
Why?
|
| Hyaluronan Receptors | 2 | 2022 | 31 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2009 | 391 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2008 | 54 | 0.070 |
Why?
|
| Gastrins | 1 | 2008 | 28 | 0.070 |
Why?
|
| Radiation, Ionizing | 1 | 2007 | 25 | 0.070 |
Why?
|
| Benzylidene Compounds | 1 | 2008 | 29 | 0.070 |
Why?
|
| Piperidones | 1 | 2008 | 32 | 0.070 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2018 | 45 | 0.070 |
Why?
|
| Regeneration | 1 | 2007 | 77 | 0.070 |
Why?
|
| Jurkat Cells | 1 | 2007 | 30 | 0.070 |
Why?
|
| Camptothecin | 1 | 2007 | 16 | 0.070 |
Why?
|
| Cytoprotection | 1 | 2006 | 24 | 0.060 |
Why?
|
| Gamma Rays | 4 | 2008 | 27 | 0.060 |
Why?
|
| Fibroblasts | 2 | 2008 | 160 | 0.060 |
Why?
|
| Cytokines | 2 | 2022 | 448 | 0.060 |
Why?
|
| Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2025 | 6 | 0.060 |
Why?
|
| Cytidine Deaminase | 1 | 2004 | 8 | 0.060 |
Why?
|
| Polyethylene Glycols | 1 | 2005 | 101 | 0.060 |
Why?
|
| Medical Oncology | 1 | 2025 | 97 | 0.050 |
Why?
|
| NF-kappa B | 3 | 2010 | 191 | 0.050 |
Why?
|
| bcl-X Protein | 3 | 2009 | 35 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2016 | 190 | 0.050 |
Why?
|
| Indomethacin | 1 | 2003 | 15 | 0.050 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2023 | 30 | 0.050 |
Why?
|
| Receptors, Prostaglandin E, EP2 Subtype | 1 | 2002 | 3 | 0.050 |
Why?
|
| Lysosomes | 1 | 2023 | 56 | 0.050 |
Why?
|
| Dynamin II | 1 | 2022 | 13 | 0.050 |
Why?
|
| Tumor Necrosis Factors | 1 | 2022 | 15 | 0.050 |
Why?
|
| Adenosine Monophosphate | 1 | 2022 | 21 | 0.050 |
Why?
|
| Dextrans | 1 | 2022 | 23 | 0.050 |
Why?
|
| Calcium-Binding Proteins | 1 | 2002 | 62 | 0.050 |
Why?
|
| Syndecan-1 | 1 | 2022 | 13 | 0.050 |
Why?
|
| Calgranulin B | 1 | 2022 | 17 | 0.050 |
Why?
|
| Quinolones | 1 | 2022 | 22 | 0.050 |
Why?
|
| Chemokines | 1 | 2022 | 74 | 0.050 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2022 | 20 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 82 | 0.050 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2022 | 25 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 169 | 0.050 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2001 | 19 | 0.050 |
Why?
|
| Cyclin D1 | 1 | 2022 | 38 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2001 | 36 | 0.050 |
Why?
|
| Intestinal Perforation | 1 | 2001 | 15 | 0.050 |
Why?
|
| Precision Medicine | 1 | 2022 | 76 | 0.040 |
Why?
|
| DNA Repair | 1 | 2022 | 82 | 0.040 |
Why?
|
| Glycolysis | 1 | 2022 | 91 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 36 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2021 | 95 | 0.040 |
Why?
|
| Neutralization Tests | 1 | 2000 | 34 | 0.040 |
Why?
|
| Lipids | 1 | 2022 | 214 | 0.040 |
Why?
|
| ROC Curve | 1 | 2021 | 144 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 226 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 190 | 0.040 |
Why?
|
| Antibodies | 1 | 2000 | 124 | 0.040 |
Why?
|
| Feces | 1 | 2020 | 114 | 0.040 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2019 | 15 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2019 | 33 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2019 | 58 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 461 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 1999 | 61 | 0.040 |
Why?
|
| Reference Values | 1 | 2018 | 199 | 0.040 |
Why?
|
| Cyclin B | 2 | 2008 | 9 | 0.040 |
Why?
|
| Pancreatectomy | 1 | 2018 | 58 | 0.040 |
Why?
|
| Rats | 1 | 2001 | 1587 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 194 | 0.040 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2008 | 37 | 0.030 |
Why?
|
| NIH 3T3 Cells | 2 | 2008 | 44 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2008 | 247 | 0.030 |
Why?
|
| Hepatitis | 1 | 2016 | 7 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2016 | 33 | 0.030 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2015 | 6 | 0.030 |
Why?
|
| Macrophages | 2 | 2008 | 302 | 0.030 |
Why?
|
| RANK Ligand | 1 | 2015 | 19 | 0.030 |
Why?
|
| Adherens Junctions | 1 | 2015 | 8 | 0.030 |
Why?
|
| Mice, Inbred ICR | 1 | 2015 | 26 | 0.030 |
Why?
|
| Femur | 1 | 2015 | 22 | 0.030 |
Why?
|
| Ceruletide | 1 | 2015 | 7 | 0.030 |
Why?
|
| X-Ray Microtomography | 1 | 2015 | 32 | 0.030 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2015 | 16 | 0.030 |
Why?
|
| Arachidonic Acid | 1 | 2015 | 19 | 0.030 |
Why?
|
| Genes, Reporter | 2 | 2008 | 87 | 0.030 |
Why?
|
| Models, Biological | 1 | 2018 | 468 | 0.030 |
Why?
|
| Mechanical Phenomena | 1 | 2015 | 21 | 0.030 |
Why?
|
| HeLa Cells | 2 | 2008 | 208 | 0.030 |
Why?
|
| Carcinoma in Situ | 1 | 2015 | 46 | 0.030 |
Why?
|
| Paris | 1 | 2014 | 2 | 0.030 |
Why?
|
| Bone Density | 1 | 2015 | 101 | 0.030 |
Why?
|
| Plant Roots | 1 | 2015 | 48 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2014 | 11 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 2014 | 59 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2004 | 36 | 0.030 |
Why?
|
| Mice, Inbred CBA | 1 | 2014 | 11 | 0.030 |
Why?
|
| Diphtheria Toxin | 1 | 2014 | 6 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 128 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 638 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2006 | 233 | 0.030 |
Why?
|
| Transcription Factor 4 | 1 | 2013 | 5 | 0.030 |
Why?
|
| Ethanol | 1 | 2015 | 124 | 0.030 |
Why?
|
| Cell Line | 1 | 2015 | 698 | 0.030 |
Why?
|
| Observer Variation | 1 | 2013 | 43 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2013 | 139 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2013 | 69 | 0.030 |
Why?
|
| Wnt Proteins | 1 | 2013 | 34 | 0.030 |
Why?
|
| Homeostasis | 1 | 2014 | 118 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2005 | 1056 | 0.020 |
Why?
|
| Emulsions | 1 | 2012 | 25 | 0.020 |
Why?
|
| Solvents | 1 | 2012 | 40 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2011 | 31 | 0.020 |
Why?
|
| Peroxidase | 1 | 2011 | 39 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2012 | 61 | 0.020 |
Why?
|
| Salmonella Infections | 1 | 2011 | 18 | 0.020 |
Why?
|
| T-Cell Intracellular Antigen-1 | 1 | 2011 | 1 | 0.020 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2011 | 4 | 0.020 |
Why?
|
| Poly(A)-Binding Proteins | 1 | 2011 | 2 | 0.020 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2011 | 6 | 0.020 |
Why?
|
| Salmonella typhimurium | 1 | 2011 | 69 | 0.020 |
Why?
|
| Luciferases, Firefly | 1 | 2010 | 4 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2011 | 86 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2010 | 7 | 0.020 |
Why?
|
| Chick Embryo | 1 | 2010 | 27 | 0.020 |
Why?
|
| Phytotherapy | 1 | 2010 | 22 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2010 | 33 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2014 | 669 | 0.020 |
Why?
|
| Leukemia | 1 | 2010 | 30 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 209 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2009 | 41 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2010 | 140 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2010 | 123 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 236 | 0.020 |
Why?
|
| G2 Phase | 1 | 2008 | 15 | 0.020 |
Why?
|
| TNF Receptor-Associated Death Domain Protein | 1 | 2008 | 3 | 0.020 |
Why?
|
| Netrin-1 | 1 | 2008 | 6 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2008 | 13 | 0.020 |
Why?
|
| G1 Phase | 1 | 2008 | 17 | 0.020 |
Why?
|
| Anaphase | 1 | 2008 | 30 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2008 | 13 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2010 | 458 | 0.020 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2008 | 11 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 44 | 0.020 |
Why?
|
| Superoxides | 1 | 2008 | 62 | 0.020 |
Why?
|
| Nerve Growth Factors | 1 | 2008 | 24 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2008 | 50 | 0.020 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2008 | 3 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2008 | 18 | 0.020 |
Why?
|
| cdc25 Phosphatases | 1 | 2008 | 3 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2008 | 16 | 0.020 |
Why?
|
| Cyclin B1 | 1 | 2008 | 7 | 0.020 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2008 | 9 | 0.020 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2008 | 6 | 0.020 |
Why?
|
| CDC2 Protein Kinase | 1 | 2008 | 15 | 0.020 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2008 | 18 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2008 | 8 | 0.020 |
Why?
|
| Tubulin | 1 | 2008 | 32 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2008 | 50 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2008 | 68 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 333 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2008 | 45 | 0.020 |
Why?
|
| Keratin-18 | 1 | 2007 | 3 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2007 | 23 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2007 | 43 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2008 | 95 | 0.020 |
Why?
|
| Pneumonia, Bacterial | 1 | 2007 | 18 | 0.020 |
Why?
|
| Pseudomonas Infections | 1 | 2007 | 25 | 0.020 |
Why?
|
| Genes, bcl-2 | 1 | 2006 | 3 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2006 | 62 | 0.020 |
Why?
|
| Protein Kinases | 1 | 2008 | 151 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2006 | 57 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2006 | 34 | 0.020 |
Why?
|
| Dimerization | 1 | 2006 | 76 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2007 | 115 | 0.020 |
Why?
|
| DNA Primers | 1 | 2006 | 147 | 0.020 |
Why?
|
| Sepsis | 1 | 2007 | 86 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2008 | 142 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2006 | 118 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2006 | 138 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2006 | 26 | 0.020 |
Why?
|
| Propionates | 1 | 2005 | 11 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2005 | 18 | 0.020 |
Why?
|
| Pichia | 1 | 2005 | 5 | 0.020 |
Why?
|
| Half-Life | 1 | 2005 | 34 | 0.010 |
Why?
|
| Protein Sorting Signals | 1 | 2005 | 18 | 0.010 |
Why?
|
| Fermentation | 1 | 2005 | 51 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2005 | 122 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 2006 | 100 | 0.010 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2005 | 55 | 0.010 |
Why?
|
| APOBEC-1 Deaminase | 1 | 2004 | 1 | 0.010 |
Why?
|
| Imidazoles | 1 | 2004 | 63 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2004 | 87 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 695 | 0.010 |
Why?
|
| Pyridines | 1 | 2004 | 108 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2004 | 157 | 0.010 |
Why?
|
| Pancreatic Juice | 1 | 2002 | 1 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2003 | 112 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2002 | 50 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 2003 | 40 | 0.010 |
Why?
|
| Hydrogen Peroxide | 1 | 2002 | 145 | 0.010 |
Why?
|
| Base Sequence | 1 | 2003 | 588 | 0.010 |
Why?
|